The Food and Drug Administration granted accelerated approval Monday to a new drug from Bristol-Myers Squibb to treat the deadliest form of skin cancer. The agency approved Opdivo for patients with hard-to-treat melanoma that cannot be removed via surgery or has spread throughout the body.